Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 lenvatinib + everolimus in unresectable advanced or metastatic renal cell carcinoma
jRCT2080222870Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib and everolimus in renal cell carcinoma (RCC), sponsored by Eisai Co., Ltd. Started May 2015; status: completed.
02
Drugs
lenvatinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080222870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222870.